The Cobourg-based group welcomes Dr Daniele Piomelli, Dr Ryan Vandrey and Professor David Casarett, MD, MA
Inc (), the medical cannabis group, has welcomed a trio of world-renowned researchers in cannabis to its scientific advisory board (SAB), it revealed Monday, who, it says, will play a key role in its clinical development programs.
Dr Raza Bokhari, FSD executive co-chairman and CEO, said in a statement the Cobourg-based group was 'honored' to welcome Dr Daniele Piomelli, Dr Ryan Vandrey and Professor David Casarett, MD, MA.
READ: FSD Pharma strikes deal with Solarvest BioEnergy to develop pharmaceutical-grade cannabinoids from algae
The latter is a professor of medicine at Duke University and the chief of palliative care for Duke Health where he directs the Duke center for palliative care.
His work in the cannabis space has included founding roles in startups, which focus on growing/dispensing (Curio Wellness; CleverLeaves), genetic testing (MelixGx), data tracking (Evio Labs), and research (Zelda; Clinicann).
Meanwhile, Dr Piomelli is the Louise Turner Arnold Chair in neurosciences and a distinguished professor of anatomy and neurobiology, pharmacology and biological chemistry at the University of California, Irvine, where he is also the director of the center for the study of cannabis.
He is also editor-in-chief of cannabis and cannabinoid research, the only peer-reviewed journal entirely dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the endocannabinoid system.
Last but not least, Dr. Vandrey is an experimental psychologist and an associate professor at the Behavioral Pharmacology research unit at Johns Hopkins university, Baltimore.
Range of studies
Vandrey has been involved with a range of studies related to the medicinal cannabis use, including the effects on sleep, cannabis withdrawal and the treatment of cannabis use disorder, cannabis product testing, and developing measures of cannabis use behavior.
Earlier this month, FSD said it had struck an agreement with Inc (TSV:SVS) to develop pharmaceutical-grade cannabinoids from algae.
Solarvest, based in Vancouver, British Columbia, employs a production platform capable of producing health products from algae.
Under the agreement, Solarvest will carry out a CBD research project to determine if its algal expression system can create pharmaceutical-grade cannabinoids.
The company develops indoor grown, pharmaceutical grade cannabis and is alos focused on research and development (R&D) of novel cannabinoid-based treatments for several central nervous system disorders.
Contact Giles at [email protected]
Follow him on @Gile74
